Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCG | P05129 | 2/20 | 0.55 |
| ▸ | PRKCB | P05771 | 2/20 | 0.55 |
| ▸ | PRKCA | P17252 | 2/20 | 0.55 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.55 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.55 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.55 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.55 |
| ▸ | STK16 | O75716 | 1/20 | 0.55 |
| ▸ | PAK3 | O75914 | 1/20 | 0.55 |
| ▸ | CDK14 | O94921 | 1/20 | 0.55 |
| ▸ | MET | P08581 | 1/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.55 |
| ▸ | KIT | P10721 | 1/20 | 0.55 |
| ▸ | PIM1 | P11309 | 1/20 | 0.55 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.55 |
| ▸ | PRKACA | P17612 | 1/20 | 0.55 |
| ▸ | PRKACB | P22694 | 1/20 | 0.55 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.55 |
| ▸ | PRKCH | P24723 | 1/20 | 0.55 |
| ▸ | CDK2 | P24941 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13915330 | 0.87 | PRKCG (0.55) | PRKCGPRKCBPRKCAPRKCEPIP5K1C | |
| SCHEMBL4989734 | 0.85 | HTR6 (0.55) | PRKCGPRKCBPRKCAPRKCEPRKCH | |
| SCHEMBL14555078 | 0.79 | PRKCG (0.62) | PRKCGPRKCBPRKCAPRKCEPIP5K1C | |
| SCHEMBL14224630 | 0.76 | PRKCG (0.56) | PRKCGPRKCBPRKCAPRKCEPIP5K1C | |
| SCHEMBL30958439 | 0.74 | PRKCG (0.57) | PRKCGPRKCBPRKCAPRKCEPIM1 | |
| Hydrochloric Acid SCHEMBL29784988 | 0.73 | PRKCG (0.77) | PRKCGPRKCBPRKCAPRKCEPIP5K1C | |
| SCHEMBL27616615 | 0.73 | HTR6 (0.60) | PRKCGPRKCBPRKCAPRKCEPRKCH | |
| SCHEMBL6438378 | 0.72 | L3MBTL1 (0.47) | CDK9L3MBTL1KDM4EPOLBCYP2D6 | |
| SCHEMBL24776887 | 0.72 | PRKCG (0.46) | PRKCGPRKCBPRKCAPRKCEPIP5K1C | |
| Enzastaurin SCHEMBL678748 | 0.71 | PRKCG (1.00) | PRKCGPRKCBPRKCAPRKCEPIP5K1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114901-B2 | Crystalline 2,5-dione-3-(1-methyl-1H-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1H-indol-3-yl]-1H-pyrrole mono-hydrochloride | ELI LILLY AND COMPANY (US) | 2012-02-14 | — | — | US | disclosed |
| US-20070270465-A1 | CRYSTALLINE 2,5-DIONE-3-(1-METHYL-1H-INDOL-3-YL)-4-[1-(PYRIDIN-2-YLMETHYL) PIPERIDIN-4-YL]-1H-INDOL-3-YL]-1H-PYRROLE MONO-HYDROCHLORIDE | BUSH JULIE K | 2007-11-22 | — | — | US | disclosed |
| EP-1523313-B1 | CRYSTALLINE 2,5-DIONE-3-(1-METHYL-1H-INDOL-3-YL)-4- 1-(PYRIDIN-2-YLMETHYL)PIPERIDIN-4-YL -1H-INDOL-3-YL -1H-PYRROLE MONO-HYDROCHLORIDE | LILLY CO ELI (US) | 2007-11-21 | — | — | EP | disclosed |
| US-20050288332-A1 | Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2ylmethyl)piperidin-4-yl]-1h- pyrrole mono-hydrochloride | DENOVO BIOPHARMA LLC | 2005-12-29 | — | — | US | disclosed |
| EP-1523313-A1 | CRYSTALLINE 2,5-DIONE-3-(1-METHYL-1H-INDOL-3-YL)-4- 1-(PYRIDIN-2-YLMETHYL)PIPERIDIN-4-YL]-1H-INDOL-3-YL]-1H-PYRROLE MONO-HYDROCHLORIDE | ELI LILLY AND COMPANY (US) | 2005-04-20 | — | — | EP | disclosed |
| WO-2004006928-A1 | CRYSTALLINE 2,5-DIONE-3-(1-METHYL-1H-INDOL-3-YL)-4-[1-(PYRIDIN-2-YLMETHYL)PIPERIDIN-4-YL]-1H-INDOL-3-YL]-1H-PYRROLE MONO-HYDROCHLORIDE | ELI LILLY AND COMPANY (US) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288332-A1 | Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2ylmethyl)piperidin-4-yl]-1h- pyrrole mono-hydrochloride | IDO1, PYCR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | PRKCG 2498/4885PRKCB 2825/4885PRKCA 2116/4885 |
| US-20070270465-A1 | CRYSTALLINE 2,5-DIONE-3-(1-METHYL-1H-INDOL-3-YL)-4-[1-(PYRIDIN-2-YLMETHYL) PIPERIDIN-4-YL]-1H-INDOL-3-YL]-1H-PYRROLE MONO-HYDROCHLORIDE | IDO1, MKI67, PYCR1 | PRKCG 2508/4885PRKCB 2859/4885PRKCA 2275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.